3xP Global is proud to announce a €1.2 million investment in BloodFlow, a pioneering healthtech company developing AI-powered infrastructure that turns routine blood test results into instant, actionable insights for clinicians.

BloodFlow operates behind the scenes, seamlessly integrating into hospital systems via a plug-and-play API that delivers rapid, explainable, and medically accurate interpretations of blood diagnostics. With its singular focus on blood test analysis, BloodFlow sets itself apart from more generalized AI tools by providing results specifically tailored for real clinical use, helping physicians save time, enhance accuracy, and improve patient outcomes.

The investment from 3xP Global, through Health Innovation Fund, aims to scale BloodFlow’s impact. Proceeds will support team growth, market entry, and a retrospective clinical study to certify the solution as a medical device. The funding will also accelerate commercial and regulatory expansion efforts, including new use cases such as supporting pharmaceutical companies with blood test interpretation during clinical trials.

"We saw in BloodFlow a focused, infrastructure-level solution that unlocks the value of underused clinical data to drive personalization and accelerate the shift from curative to preventative medicine," said Raúl Saraiva, Chief Scientific Officer & Venture Partner at 3xP Global. “Tiago Cunha Costa, Bloodflow Founder, brings a rare combination of technical depth and entrepreneurial drive, and we’re excited to back a team turning everyday diagnostics into high-impact, real-time decisions that truly move the needle on healthspan."

‍

This investment reflects 3xP Global’s commitment to supporting enabling technologies that foster earlier and more precise healthcare interventions. By transforming standard diagnostics into dynamic clinical decision-making tools, BloodFlow reinforces our fund’s strategy to extend healthspan and support scalable solutions across care settings.

‍

"We are thrilled to have 3xP Global as a strategic investor in BloodFlow’s journey," said Tiago Cunha Costa, Founder and CEO of BloodFlow. "Their investment brings invaluable expertise and support as we scale our solution to transform clinical workflows and improve patient outcomes across Europe."

As BloodFlow advances toward broader clinical adoption, 3xP Global remains committed to backing infrastructure solutions that bridge innovation and impact, empowering healthcare systems to act faster, smarter, and earlier.